Telomere shortening: A biological marker of sporadic colorectal cancer with normal expression of p53 and mismatch repair proteins

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 4, 2014, Pages 236-244

  Haghighi, Mahdi Montazer ^a   Aghagolzadeh, Parisa ^b   Zadeh, Saman Milani ^c   Molaei, Mahsa ^c   Zali, Mohammad Reza ^c   Radpour, Ramin ^b,d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b UNIVERSITY OF BERN   (Switzerland)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER TISSUE; CELL AGING; CELL PROLIFERATION; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DESCENDING COLON; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENETIC MARKER; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGMOID; TELOMERE SHORTENING; BASE MISPAIRING; COLORECTAL TUMOR; DNA REPAIR; GENETICS; MIDDLE AGED; PATHOLOGY; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BASE PAIR MISMATCH; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA REPAIR; GENES, P53; HUMANS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TELOMERE SHORTENING; TUMOR MARKERS, BIOLOGICAL;

EID: 84897485600     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0436     Document Type: Article

References (41)

1. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J (2012) Molecular pathways in colorectal cancer. J Gastroenterol Hepatol 27:1423-1431.
2. Artandi SE, DePinho RA (2010) Telomeres and telomerase in cancer. Carcinogenesis 31:9-18.
3. Atzmon G, Cho M, Cawthon RM, et al. (2010) Evolution in health and medicine Sackler colloquium: genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci USA 107Suppl 1:1710-1717.
4. Bisoffi M, Heaphy CM, Griffith JK (2006) Telomeres: prognostic markers for solid tumors. Int J Cancer 119:2255-2260.
5. Blackburn EH (1991) Structure and function of telomeres. Nature 350:569-573.
6. Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6:611-622.
7. Gertler R, Rosenberg R, Stricker D, et al. (2004) Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 22:1807-1814.
8. Gervaz P, Bucher P, Morel P (2004) Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol 88:261-266.
9. Gisselsson D, Jonson T, Petersen A, et al. (2001) Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA 98:12683-12688.
10. Gonzalez-Gonzalez M, Garcia JG, Montero JA, et al. (2013) Genomics and proteomics approaches for biomarker discovery in sporadic colorectal cancer with metastasis. Cancer Genomics Proteomics 10:19-25.
11. Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079-1099.
12. Hahn WC (2003) Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 21:2034-2043.
13. Harley CB (1991) Telomere loss: mitotic clock or genetic time bomb? Mutat Res 256:271-282.
14. Harley CB (2008) Telomerase and cancer therapeutics. Nat Rev Cancer 8:167-179.
15. Hastie ND, Dempster M, Dunlop MG, et al. (1990) Telomere reduction in human colorectal carcinoma and with ageing. Nature 346:866-868.
16. Heaphy CM, Baumgartner KB, Bisoffi M, et al. (2007) Telomere DNA content predicts breast cancer-free survival interval. Clin Cancer Res 13:7037-7043.
17. Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101:403-408.
18. Jouret-Mourin A, Geboes K (2012) Serrated lesions of the colorectum, a new entity: what should a clinician/endoscopist know about it? Acta Gastroenterol Belg 75:197-202.
19. Jover R, Paya A, Alenda C, et al. (2004) Defective mismatchrepair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. Am J Clin Pathol 122:389-394.
20. Katayama S, Shiota G, Oshimura M, Kawasaki H (1999) Clinical usefulness of telomerase activity and telomere length in the preoperative diagnosis of gastric and colorectal cancer. J Cancer Res Clin Oncol 125:405-410.
21. Koretz RL (1993) Malignant polyps: are they sheep in wolves' clothing? Ann Intern Med 118:63-68.
22. Lin KW, Yan J (2005) The telomere length dynamic and methods of its assessment. J Cell Mol Med 9:977-989.
23. Mambo E, Chatterjee A, Xing M, et al. (2005) Tumor-specific changes in mtDNA content in human cancer. Int J Cancer 116:920-924.
24. Meeker AK, Hicks JL, Gabrielson E, et al. (2004) Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol 164:925-935.
25. Montazer Haghighi M, Radpour R, Aghajani K, et al. (2009) Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer. Int J Colorectal Dis 24:885-893.
26. Muraki K, Nyhan K, Han L, Murnane JP (2012) Mechanisms of telomere loss and their consequences for chromosome instability. Front Oncol 2:135.
27. O'Sullivan J, Risques RA, Mandelson MT, et al. (2006) Telomere length in the colon declines with age: a relation to colorectal cancer? Cancer Epidemiol Biomarkers Prev 15:573-577.
28. Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagn 10:13-27.
29. Radpour R, Barekati Z, Haghighi MM, et al. (2010) Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol 23:763-772.
30. Radpour R, Barekati Z, Kohler C, et al. (2009) New trends in molecular biomarker discovery for breast cancer. Genet Test Mol Biomarkers 13:565-571.
31. Radpour R, Haghighi MM, Fan AX, et al. (2008) Highthroughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Mol Cancer Res 6:1702-1709.
32. Raynaud CM, Jang SJ, Nuciforo P, et al. (2008) Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann Oncol 19:1875-1881.
33. Rha SY, Park KH, Kim TS, et al. (1999) Changes of telomerase and telomere lengths in paired normal and cancer tissues of breast. Int J Oncol 15:839-845.
34. Rial NS, Zell JA, Cohen AM, Gerner EW (2012) Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Rev Gastroenterol Hepatol 6:507-517.
35. Saldanha SN, Andrews LG, Tollefsbol TO (2003) Assessment of telomere length and factors that contribute to its stability. Eur J Biochem 270:389-403.
36. Srinivasan M, Sedmak D, Jewell S (2002) Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 161:1961-1971.
37. Takagi S, Kinouchi Y, Hiwatashi N, et al. (1999) Telomere shortening and the clinicopathologic characteristics of human colorectal carcinomas. Cancer 86:1431-1436.
38. Terrin L, Rampazzo E, Pucciarelli S, et al. (2008) Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 14:7444-7451.
39. Walther A, Houlston R, Tomlinson I (2008) Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 57:941-950.
40. Wright WE, Shay JW (2000) Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat Med 6:849-851.
41. Zhang A, Wang J, Zheng B, et al. (2004) Telomere attrition predominantly occurs in precursor lesions during in vivo carcinogenic process of the uterine cervix. Oncogene 23: 7441-7447.